Sunshine Biopharma, Inc.
SBFMSunshine Biopharma, Inc. in brief
Sunshine Biopharma, Inc. is a listed company in the Pharmaceutical industry, based in Montreal, Canada. Its market value was $3 M on 30 October 2026, which makes it the 27,570th largest listed company in the world and the 1,751st largest in Canada on this site. In the year to December 2025 it had sales of $36 M and a net loss of $6 M. It employs about 50 people. Its shares trade under the symbol SBFM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sunshine Biopharma, Inc.
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 71 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation which develops and sells OTC supplements.
In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.
From the company's annual report filed with the US SEC: read the report
Sunshine Biopharma, Inc. timeline
- 2007
- ✎Renamed mountain west business solutions,incFormerly mountain state business solutions,inc.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2009
- ✎Renamed Sunshine Biopharma, IncFormerly mountain west business solutions,inc.
- 2025
- 💰Record revenue of $36 millionFY2025, the highest of the 7 years on record.
Events of Sunshine Biopharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #1,124 (Jan 2022) · #1,198 (Dec 2022) · #1,197 (Jul 2023) · #1,375 (Jan 2024) · #55 (Mar 2026) · #837 (Aug 2026) · #1,751 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.1×
- Price / book
- 0.1×
- Free cash flow yield
- -200.7%
- Net margin (TTM)
- -17.4%
- Operating margin
- -17.2%
- Return on equity
- -26.8%
- Liabilities / assets
- 23.4%
- Net debt
- $-0M
- Revenue growth
- +4.1%
- R&D / revenue
- 1.7%
- Revenue per employee
- $726 K
- Profit per employee
- $-120 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $36M | +4.1% | $-6M | $-6M | -16.5% |
| Dec 2024 | $35M | +44.7% | $-6M | $-5M | -14.7% |
| Dec 2023 | $24M | +453.8% | $-5M | $-5M | -18.7% |
| Dec 2022 | $4M | +1791.3% | $-27M | $-27M | -614.7% |
| Dec 2021 | $0M | +228.6% | $-2M | $-12M | -5408.7% |
| Dec 2020 | $0M | +250.0% | $-1M | $-3M | -3971.4% |
| Dec 2019 | $0M | — | $-1M | $-2M | -8300.0% |
| Dec 2018 | — | — | $-1M | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-6M | — | — |
| Dec 2024 | $-13M | $2M | $-14M | $-7.32 | — |
| Dec 2023 | $-9M | $0M | $-9M | $-351.36 | — |
| Dec 2022 | $-5M | $0M | $-5M | $-1.76 | — |
| Dec 2021 | $-2M | $0M | $-2M | $-4.76 | — |
| Dec 2020 | $-1M | $0M | $-1M | — | — |
| Dec 2019 | $-1M | $0M | $-1M | — | — |
| Dec 2018 | $-1M | $0M | $-1M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $9M (+0.2% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 2026DEF 14AProxy statement
- Oct 14, 20268-KCurrent reportShareholder vote
- Oct 9, 20268-KCurrent reportMaterial agreement · Other events
- Oct 9, 2026424B4IPO prospectus
- Oct 2, 2026S-1IPO registration
- Sep 16, 20268-KCurrent reportShareholder vote
- Sep 11, 20268-KCurrent reportOther events
- Aug 28, 2026S-1IPO registration
- Aug 28, 20268-KCurrent reportDirectors or officers changed
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportOther events
Official filings of Sunshine Biopharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $36 M
- Operating income
- $-6 M
- Net income
- $-6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $30 M
- Total liabilities
- $7 M
- Total equity
- $23 M
As of December-2025
Top 15 institutional investors in Sunshine Biopharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 60,309 | +45,335 (+302.76%) | 7.32% | $0 M | Nov 12, 2026 |
| 2 | UBS Group AG | 34,715 | New | 4.21% | $0 M | Nov 10, 2026 |
| 3 | Virtu Financial LLC | 22,216 | New | 2.70% | $0 M | Nov 17, 2026 |
| 4 | XTX Topco Ltd | 20,157 | New | 2.45% | $0 M | Nov 16, 2026 |
| 5 | Susquehanna International Group, LLP | 18,397 | New | 2.23% | $0 M | Nov 16, 2026 |
| 6 | Pinnacle Financial Group, Inc. | 1,200 | — | 0.15% | $0 M | Nov 16, 2026 |
| 7 | Morgan Stanley | 385 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 8 | SBI Securities Co., Ltd. | 213 | +51 (+31.48%) | 0.03% | $0 M | Oct 22, 2026 |
| 9 | Caitong International Asset Management Co., Ltd | 50 | +49 (+4900.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 10 | Robinhood Markets, Inc. | 39 | — | 0.00% | $0 M | Nov 18, 2026 |
| 11 | Jpmorgan Chase & Co | 8 | New | 0.00% | $0 M | Nov 12, 2026 |
| 12 | National Bank Of Canada /fi/ | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 13 | Osaic Holdings, Inc. | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 14 | TD Waterhouse Canada Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 15 | Strive Financial Group ,LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Insider trading at Sunshine Biopharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David NatanDirector | Grant or award | +58,300 | — | — | 68,300 | Form 4 |
| filed | David NatanDirector | Grant or award | +100,000 | — | — | 100,000 | Form 4 |
| filed | Steve N. SlilatyChief Executive Officer, Director, 10% owner | Buy | +100,000 | $0.100 | $10 K | 130,000 | Form 4 |
| filed | Steve N. SlilatyChief Executive Officer, Director, 10% owner | Buy | +20,000 | $0.100 | $2 K | 30,000 | Form 4 |
| filed | Camille SebaalyCFO/Secretary | Buy | +30,000 | $0.760 | $23 K | 174,465 | Form 4 |
| filed | Camille SebaalyCFO/Secretary | Buy | +25,000 | $1.220 | $31 K | 144,465 | Form 4 |
| filed | Steve N. SlilatyChief Executive Officer, Director | Disposal to the company | -990,000 | $0.100 | $99 K | 10,000 | Form 4 |
| filed | Camille SebaalyCFO/Secretary, Director | Grant or award | +20.00 M | — | — | 23.89 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sunshine Biopharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $0M |
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q2 2024 | Q2 2025 | $0M |
| Q1 2024 | Q1 2025 | $3.1M |
| Q4 2023 | Q4 2024 | $0M |
Trading halts
- 2026-10-23 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-10-07 15:59 UTC, code LUDP, resumed 16:04 UTC
- 2026-10-07 15:37 UTC, code LUDP, resumed 15:42 UTC
- 2026-10-07 15:30 UTC, code LUDP, resumed 15:35 UTC
- 2026-10-07 15:25 UTC, code LUDP, resumed 15:30 UTC
Fails to deliver
- : 921 shares at $3.33
- : 10,080 shares at $3.11
- : 40,087 shares at $2.96
- : 15,815 shares at $2.65
- : 79,833 shares at $0.24
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sunshine Biopharma, Inc. scorecard#
Passes 8 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.1×Price to book 0.1× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median0.1×Price to sales 0.1× against Pharmaceutical's median of 3.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year4.1%Revenue up 4.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years102.8%102.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median102.8%102.8% a year against Pharmaceutical's median of 2.5% (65 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$3 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-17.2%-17.2% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-25.7%-25.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-17.2%-17.2% in fiscal 2025 against -620.7% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.17 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-1.92Z-score -1.92 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sunshine Biopharma, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -17.2% | 1.8% | |
| Net margin | -16.5% | -1.5% | |
| Return on equity | -25.7% | -0.9% | |
| Revenue growth, 3 years a year | 102.9% | 2.5% | |
| Revenue growth | 4.1% | 7.3% | |
| Free cash flow margin | -15.2% | 6.0% |
5of 8on the Piotroski tests of financial strength
- Net loss of $6 million, the 16th loss-making year in a row.
- Free cash flow was negative: -$6 million.
- Revenue has grown 6 years in a row.
Sunshine Biopharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 36,306+4.1%100% | 34,874+44.7%100% | 24,093+454%100% | 4,346+1802%100% | 228+220%100% | 71+238%100% | 21—100% | 0r447—— | 0—— | 0—— | |
| Cost of revenue | 24,050−0.6%66.2% | 24,204+53.6%69.4% | 15,754+495%65.4% | 2,649+2148%61.0% | 118+356%51.6% | 26+134%36.2% | 11—52.3% | 0r391—— | 0—— | — | |
| Gross profit | 12,256+14.9%33.8% | 10,670+27.9%30.6% | 8,339+392%34.6% | 1,697+1434%39.0% | 111+143%48.4% | 46+352%63.8% | 10—47.7% | 0r56—— | 0—— | — | |
| Research and development | 604−35.3%1.7% | 934−49.7%2.7% | 1,856+129%7.7% | 812+20.8%18.7% | 672+38801%294% | 1.7r61−88.6%2.4% | 15+18.8%72.0% | 13—— | 0−100%— | 33—— | |
| General and administrative | 18,483+12.1%50.9% | 16,482+25.6%47.3% | 13,124−54.3%54.5% | 28,697+1025%660% | 2,551+310%1117% | 622−4.5%872% | 652−44.0%3086% | 1,164r1,223+35.8%— | 857−13.7%— | 993—— | |
| Operating income | −6,227—−17.2% | −5,812—−16.7% | −4,785—−19.9% | −27,001—−621% | −2,440—−1068% | −577—−808% | −642—−3038% | −1,164r−1,167—— | −857—— | −993—— | |
| Interest expense and finance costs | 0−100%0.0% | 8.8−93.6%0.0% | 137+248%0.6% | 39−88.0%0.9% | 329+95.6%144% | 168+45.0%235% | 116−19.2%549% | 143r159+36.9%— | 105+202%— | 35—— | |
| Other non-operating income (expense) | 273−38.3%0.8% | 443−34.3%1.3% | 674+37.7%2.8% | 490—11.3% | −9,996—−4376% | −2,207—−3091% | −436—−2066% | −974r−990—— | −183—— | −2,504—— | |
| Income before tax | −5,954—−16.4% | −5,369—−15.4% | −4,111—−17.1% | −26,511—−610% | −12,436—−5444% | — | — | — | — | — | |
| Income tax | 22—0.1% | −235−159%−0.7% | 395+69.4%1.6% | 233—5.4% | 0—0.0% | 0—0.0% | — | — | — | — | |
| Income from continuing operations | — | — | — | — | — | −2,784—−3899% | −1,078—−5104% | −2,138—— | — | — | |
| Income from discontinued operations | — | — | — | — | — | 0—0.0% | −582—−2757% | −18—— | — | — | |
| Net income including minority interests | — | — | — | — | −12,457—−5453% | −2,784r−2,784—−3899% | −1,660—−7861% | −2,156r−2,160—— | −1,040—— | −3,497r−3,497—— | |
| Net income attributable to shareholders | −5,975—−16.5% | −5,134—−14.7% | −4,506—−18.7% | −26,744—−615% | −12,436—−5444% | −2,784—−3899% | −1,660—−7861% | −2,156—— | −1,040—— | −3,497—— | |
| Earnings per share, basic | -1.44—— | -7.32—— | -351.36r-0.19—— | -1.76—— | -4.76—— | -2.73r-0.01—— | -0.15—— | -0.71r-0.04—— | -0.02r0.00—— | -0.01—— | |
| Earnings per share, diluted | — | -7.32—— | -351.36r-0.19—— | -1.76—— | -4.76—— | — | — | — | — | — | |
| Shares, weighted average (basic) | 4.2+492%— | 0.7+5372%— | 0.0r24−99.9%— | 15+481%— | 2.6+156%— | 1.0r204−90.7%— | 11+259%— | 3.0r61−93.0%— | 44r873−89.7%— | 425—— | |
| Shares, weighted average (diluted) | — | 0.7+5372%— | 0.0r24−99.9%— | 15+481%— | 2.6—— | — | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 9,123−5.8%30.3% | 9,687−40.5%31.7% | 16,292−25.4%59.6% | 21,826+967%74.6% | 2,045+107%92.8% | 990+2344%94.7% | 41−63.4%41.3% | 111r115+2.8%9.6% | 108+87.2%41.8% | 57—89.2% | |
| Receivables | 3,460−10.6%11.5% | 3,868+51.6%12.7% | 2,552+33.5%9.3% | 1,912+24421%6.5% | 7.8+307%0.4% | 1.9+346%0.2% | 0.4—0.4% | 0r95—0.0% | 0—0.0% | — | |
| Inventory | 13,472+19.5%44.8% | 11,278+96.7%36.9% | 5,735+74.3%21.0% | 3,290+3014%11.3% | 106+344%4.8% | 24+49.4%2.3% | 16—16.2% | 0—0.0% | — | — | |
| Other current assets | — | — | — | — | — | 2.8+121%0.3% | 1.3−6.4%1.3% | 1.3−86.1%0.1% | 9.7+860%3.8% | 1.0—1.6% | |
| Current assets | 26,854+3.4%89.3% | 25,966+4.3%85.0% | 24,890−8.9%91.0% | 27,312+1144%93.4% | 2,196+114%99.7% | 1,026+1462%98.1% | 66−94.0%66.9% | 1,101r212+840%96.1% | 117+100%45.5% | 58—90.8% | |
| Property, plant and equipment | 557+2.1%1.9% | 546+49.2%1.8% | 366−7.2%1.3% | 394+5483%1.3% | 7.1−63.8%0.3% | 20−39.8%1.9% | 32−28.1%33.1% | 45r269−24.8%3.9% | 60+909%23.3% | 5.9—9.2% | |
| Right-of-use (leased) assets | 779−16.8%2.6% | 936+44.7%3.1% | 647−14.9%2.4% | 760—2.6% | 0—0.0% | — | — | 0—0.0% | — | — | |
| Goodwill | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | 6660.0%678% | 666—58.1% | 0—0.0% | — | |
| Other intangible assets | 1,889−37.4%6.3% | 3,020+109%9.9% | 1,444+85.9%5.3% | 777—2.7% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Non-current assets | 3,226−29.8%10.7% | 4,594+87.0%15.0% | 2,457—9.0% | — | — | 20—1.9% | — | 935—81.6% | — | — | |
| Total assets | 30,079−1.6%100% | 30,560+11.8%100% | 27,347−6.5%100% | 29,244+1228%100% | 2,203+111%100% | 1,045+965%100% | 98−91.4%100% | 1,147+345%100% | 257+300%100% | 64—100% | |
| Accounts payable | 5,664+2.2%18.8% | 5,543+114%18.1% | 2,585−7.8%9.5% | 2,803r2,803+6427%9.6% | 43−31.7%1.9% | 63−35.1%6.0% | 97−16.4%98.7% | 116r191+500%10.1% | 19−31.3%7.5% | 28—43.7% | |
| Current liabilities | 6,444+2.0%21.4% | 6,315+13.7%20.7% | 5,552−19.9%20.3% | 6,931+7497%23.7% | 91−91.3%4.1% | 1,051+26.1%101% | 834−8.7%849% | 912+21.5%79.6% | 751+174%292% | 274—426% | |
| Lease liabilities (non-current) | 597−19.9%2.0% | 745+38.2%2.4% | 539−16.1%2.0% | 642—2.2% | 0—0.0% | — | — | 0—0.0% | — | — | |
| Non-current liabilities | 597−19.9%2.0% | 745+26.7%2.4% | 588−14.2%2.1% | 685−63.9%2.3% | 1,900—86.3% | — | — | 290—25.3% | — | — | |
| Total liabilities | 7,041−0.3%23.4% | 7,060+15.0%23.1% | 6,140−19.4%22.5% | 7,616+282%26.0% | 1,991−0.5%90.4% | 2,000+140%191% | 834−30.7%849% | 1,202+44.7%105% | 831+203%323% | 274—426% | |
| Retained earnings | −75,015—−249% | −69,040—−226% | −63,906—−234% | −59,400—−203% | −32,655—−1482% | −20,219—−1934% | −17,435—−17765% | −15,774—−1376% | −13,618—−5289% | −12,578—−19530% | |
| Shareholders' equity | 23,038−2.0%76.6% | 23,501+10.8%76.9% | 21,207−1.9%77.5% | 21,628+10118%74.0% | 212—9.6% | −955—−91.3% | −735—−749% | −56—−4.9% | −573r−573—−223% | −210—−326% | |
| Total liabilities and equity | 30,079−1.6%100% | 30,560+11.8%100% | 27,347−6.5%100% | 29,244+1228%100% | 2,203+111%100% | 1,045+965%100% | 98−91.4%100% | 1,147+345%100% | 257+300%100% | 64—100% | |
| Shares outstanding | 0.0r4.9−99.0%— | 2.6+18313%— | 0.0r28−99.9%— | 23+772%— | 2.6+49.6%— | 1.7r346−95.1%— | 35+725%— | 4.3r86−90.7%— | 46r919−94.0%— | 769—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 332+48.6%0.9% | 224+49.9%0.6% | 149+493%0.6% | 25+97.5%0.6% | 13−9.4%5.6% | 14+2.1%19.7% | 14−72.1%65.2% | 49+645%— | 6.6−89.1%— | 61—— | |
| Share-based compensation | — | — | — | — | — | 272−1.9%381% | 277−63.3%1313% | 755+45.2%— | 520+4.2%— | 499r702—— | |
| Cash from operating activities | −5,331—−14.7% | −12,525r−12,531—−35.9% | −8,775—−36.4% | −5,248—−121% | −1,829—−801% | −657—−920% | −496—−2347% | −513—— | −544—— | −314—— | |
| Capital expenditure | −174—−0.5% | −1,657—−4.8% | −82—−0.3% | −194—−4.5% | 0—0.0% | −1.2—−1.7% | −0.9—−4.1% | −19—— | −3.7—— | −3.4—— | |
| Intangible assets bought | −662—−1.8% | −322—−0.9% | −706—−2.9% | −111—−2.6% | 0—0.0% | — | — | — | — | 0—— | |
| Cash from investing activities | −836—−2.3% | −1,979r−2,321—−5.7% | −656—−2.7% | −14,619—−336% | 0—0.0% | −1.2—−1.7% | −15—−72.3% | −14—— | −84—— | −3.4—— | |
| Shares issued | 1,829−78.5%5.0% | 8,522+108%24.4% | 4,089−86.5%17.0% | 30,367—699% | 0—0.0% | — | — | 0−100%— | 64−38.6%— | 104—— | |
| Shares bought back | 0—0.0% | −3,140—−9.0% | −541—−2.2% | — | — | — | — | — | — | — | |
| Cash from financing activities | 4,748−46.9%13.1% | 8,942r9,290+161%25.6% | 3,426−91.3%14.2% | 39,465+1259%908% | 2,905+80.6%1272% | 1,608+264%2252% | 442−16.2%2094% | 528−21.3%— | 671+107%— | 325—— | |
| Exchange-rate effect on cash | — | 0—0.0% | −63—−0.3% | −1.1—−0.0% | 0r−20—0.0% | −0.4—−0.5% | −5.9−187%−27.9% | 6.8−2.1%— | 6.9—— | −0.3—— | |
| Change in cash | — | — | — | — | — | 950—1330% | −69−7532%−326% | 0.9−97.9%— | 43+517%— | 7.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 35,372−5.2%100% | 9,442+0.3%100% | 9,264−1.6%100% | 8,089−9.1%100% | 8,577*−10.6%100% | 9,417+11.6%100% | 9,410+1.2%100% | 8,901+18.0%100% | 9,595*+24.9%100% | 8,435—100% | 9,303—100% | 7,541—100% | 7,680*—100% | |
| Cost of revenue | 24,634−1.5%69.6% | 6,341−0.0%67.2% | 6,837+14.2%73.8% | 5,908−4.3%73.0% | 5,548*−14.7%64.7% | 6,344+13.9%67.4% | 5,987−13.8%63.6% | 6,171+19.0%69.3% | 6,502*+27.2%67.8% | 5,569—66.0% | 6,947—74.7% | 5,187—68.8% | 5,112*—66.6% | |
| Gross profit | 10,738−12.8%30.4% | 3,102+0.9%32.8% | 2,427−29.1%26.2% | 2,181−20.1%27.0% | 3,029*−2.1%35.3% | 3,074+7.2%32.6% | 3,423+45.3%36.4% | 2,730+16.0%30.7% | 3,093*+20.4%32.2% | 2,866—34.0% | 2,356—25.3% | 2,354—31.2% | 2,568*—33.4% | |
| Research and development | 120−82.4%0.3% | 1.6−98.7%0.0% | 13−93.3%0.1% | 32−85.3%0.4% | 74*−50.8%0.9% | 119−5.6%1.3% | 196−55.0%2.1% | 215−3.0%2.4% | 149*−81.7%1.6% | 126—1.5% | 436—4.7% | 222—2.9% | 816*—10.6% | |
| General and administrative | 16,827−10.5%47.6% | 4,392+5.6%46.5% | 4,040−26.3%43.6% | 3,577−11.2%44.2% | 4,819*−6.1%56.2% | 4,160+4.7%44.2% | 5,478+51.1%58.2% | 4,026+8.7%45.2% | 5,131*+36.6%53.5% | 3,973—47.1% | 3,625—39.0% | 3,705—49.1% | 3,755*—48.9% | |
| Operating income | −6,089—−17.2% | −1,290—−13.7% | −1,613—−17.4% | −1,396—−17.3% | −1,790*—−20.9% | −1,087—−11.5% | −2,055—−21.8% | −1,296—−14.6% | −2,038*—−21.2% | −1,106—−13.1% | −1,268—−13.6% | −1,351—−17.9% | −1,187*—−15.5% | |
| Interest expense and finance costs | — | — | — | — | 0*−100%0.0% | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 8.5*−71.7%0.1% | 0—0.0% | 0.2—0.0% | 49—0.7% | 30*—0.4% | |
| Other non-operating income (expense) | 261—0.7% | 3.0−95.4%0.0% | 49−34.6%0.5% | 152+100%1.9% | 57*—0.7% | 65−47.2%0.7% | 75−82.6%0.8% | 76−14.9%0.9% | −249*−258%−2.6% | 124—1.5% | 430—4.6% | 89—1.2% | 157*—2.1% | |
| Income before tax | −5,828—−16.5% | −1,287—−13.6% | −1,564—−16.9% | −1,244—−15.4% | −1,733*—−20.2% | −1,021—−10.8% | −1,980—−21.0% | −1,220—−13.7% | −2,287*—−23.8% | −983—−11.6% | −838—−9.0% | −1,261—−16.7% | −1,030*—−13.4% | |
| Income tax | 345—1.0% | −64—−0.7% | 0—0.0% | 0—0.0% | 408*—4.8% | −137−164%−1.5% | −209—−2.2% | −40−280%−0.5% | −129*−158%−1.3% | 215—2.6% | −344—−3.7% | 22—0.3% | 220*—2.9% | |
| Net income attributable to shareholders | −6,173—−17.5% | −1,224—−13.0% | −1,564—−16.9% | −1,244—−15.4% | −2,141*—−25.0% | −884—−9.4% | −1,771—−18.8% | −1,180—−13.3% | −2,158*—−22.5% | −1,198—−14.2% | −494—−5.3% | −1,284—−17.0% | −1,250*—−16.3% | |
| Earnings per share, basic | — | -5.20—— | -1.15—— | -0.25—— | — | -38.80r-0.19—— | -3.94r-0.39—— | -0.44—— | — | -0.94—— | -9.94—— | -2.00—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | -0.82—— | -0.44—— | — | — | -43.48—— | -2.00—— | — | |
| Shares, weighted average (basic) | 0.2+933%— | 0.2+933%— | 1.4+204%— | 4.9+81.5%— | — | 0.0r4.6−98.2%— | 0.4r4.5+804%— | 2.7+322%— | — | 1.3—— | 0.0—— | 0.6—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | 3.6+8714%— | 2.7+322%— | — | 1.3—— | 0.0r0.0—— | 0.6—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 14,619—43.2% | 14,619+57.1%43.2% | 13,748+33.4%40.9% | 6,913−14.9%24.8% | 9,123−5.8%30.3% | 9,306−23.8%29.6% | 10,305−10.4%32.2% | 8,125−53.4%27.8% | 9,687−40.5%31.7% | 12,207—40.6% | 11,508—39.3% | 17,434—54.7% | 16,292—59.6% | |
| Receivables | 3,892—11.5% | 3,892−6.3%11.5% | 4,035+12.5%12.0% | 4,012+16.4%14.4% | 3,460−10.6%11.5% | 4,156+29.1%13.2% | 3,588−9.7%11.2% | 3,445+21.8%11.8% | 3,868+51.6%12.7% | 3,219—10.7% | 3,974—13.6% | 2,828—8.9% | 2,552—9.3% | |
| Inventory | 11,662—34.4% | 11,662−17.1%34.4% | 12,122−6.9%36.0% | 13,168+11.1%47.1% | 13,472+19.5%44.8% | 14,064+43.2%44.7% | 13,019+53.3%40.7% | 11,857+54.0%40.6% | 11,278+96.7%36.9% | 9,821—32.7% | 8,491—29.0% | 7,698—24.1% | 5,735—21.0% | |
| Current assets | 31,004—91.6% | 31,004+10.9%91.6% | 30,665+10.1%91.2% | 24,783+1.2%88.7% | 26,854+3.4%89.3% | 27,967+7.6%88.8% | 27,851+8.2%87.1% | 24,481−15.1%83.9% | 25,966+4.3%85.0% | 25,982—86.4% | 25,749—87.9% | 28,831—90.4% | 24,890—91.0% | |
| Property, plant and equipment | 362—1.1% | 362−39.5%1.1% | 477−25.3%1.4% | 516−0.7%1.8% | 557+2.1%1.9% | 598+1.2%1.9% | 638+17.9%2.0% | 520+29.4%1.8% | 546+49.2%1.8% | 591—2.0% | 541—1.8% | 402—1.3% | 366—1.3% | |
| Right-of-use (leased) assets | 599—1.8% | 599−27.0%1.8% | 648−27.4%1.9% | 713−20.9%2.6% | 779−16.8%2.6% | 820+51.5%2.6% | 893+58.3%2.8% | 901+50.1%3.1% | 936+44.7%3.1% | 541—1.8% | 564—1.9% | 600—1.9% | 647—2.4% | |
| Goodwill | — | — | — | — | — | — | — | — | 0—0.0% | — | — | — | 0—0.0% | |
| Other intangible assets | 1,893—5.6% | 1,893−5.8%5.6% | 1,842−26.0%5.5% | 1,918−39.9%6.9% | 1,889−37.4%6.3% | 2,009−31.7%6.4% | 2,491+1.8%7.8% | 3,193+54.6%10.9% | 3,020+109%9.9% | 2,943—9.8% | 2,447—8.4% | 2,066—6.5% | 1,444—5.3% | |
| Non-current assets | 2,855—8.4% | 2,855−18.9%8.4% | 2,967−27.9%8.8% | 3,147−33.1%11.3% | 3,226−29.8%10.7% | 3,520−13.6%11.2% | 4,114+15.8%12.9% | 4,706—16.1% | 4,594+87.0%15.0% | 4,075—13.6% | 3,552—12.1% | — | 2,457—9.0% | |
| Total assets | 33,859—100% | 33,859+7.5%100% | 33,633+5.2%100% | 27,930−4.3%100% | 30,079−1.6%100% | 31,487+4.8%100% | 31,965+9.1%100% | 29,187−8.5%100% | 30,560+11.8%100% | 30,057—100% | 29,301—100% | 31,899—100% | 27,347—100% | |
| Accounts payable | 4,326—12.8% | 4,326−29.5%12.8% | 4,852+1.1%14.4% | 5,105+1.6%18.3% | 5,664+2.2%18.8% | 6,137+47.6%19.5% | 4,797−2.7%15.0% | 5,025+39.0%17.2% | 5,543+114%18.1% | 4,157—13.8% | 4,930—16.8% | 3,615—11.3% | 2,585—9.5% | |
| Current liabilities | 4,794—14.2% | 4,794−27.9%14.2% | 5,619+0.8%16.7% | 5,878+2.0%21.0% | 6,444+2.0%21.4% | 6,651+46.9%21.1% | 5,574+5.2%17.4% | 5,762−11.8%19.7% | 6,315+13.7%20.7% | 4,528—15.1% | 5,299—18.1% | 6,533—20.5% | 5,552—20.3% | |
| Lease liabilities (non-current) | 427—1.3% | 427−32.9%1.3% | 476−32.7%1.4% | 536−25.8%1.9% | 597−19.9%2.0% | 637+44.6%2.0% | 707+52.6%2.2% | 722+45.3%2.5% | 745+38.2%2.4% | 440—1.5% | 463—1.6% | 497—1.6% | 539—2.0% | |
| Non-current liabilities | 427—1.3% | 427−32.9%1.3% | 476−32.7%1.4% | 536−25.8%1.9% | 597−19.9%2.0% | 637+30.2%2.0% | 707+38.1%2.2% | 722+32.3%2.5% | 745+26.7%2.4% | 489—1.6% | 512—1.7% | 546—1.7% | 588—2.1% | |
| Total liabilities | 5,222—15.4% | 5,222−28.4%15.4% | 6,095−3.0%18.1% | 6,414−1.1%23.0% | 7,041−0.3%23.4% | 7,288+45.3%23.1% | 6,280+8.1%19.6% | 6,485−8.4%22.2% | 7,060+15.0%23.1% | 5,018—16.7% | 5,811—19.8% | 7,079—22.2% | 6,140—22.5% | |
| Retained earnings | −79,047—−233% | −79,047—−233% | −77,823—−231% | −76,259—−273% | −75,015—−249% | −72,874—−231% | −71,990—−225% | −70,220—−241% | −69,040—−226% | −66,882—−223% | −65,684—−224% | −65,189—−204% | −63,906—−234% | |
| Shareholders' equity | 28,637—84.6% | 28,637+18.3%84.6% | 27,538+7.2%81.9% | 21,517−5.2%77.0% | 23,038−2.0%76.6% | 24,199−3.4%76.9% | 25,685+9.3%80.4% | 22,702−8.5%77.8% | 23,501+10.8%76.9% | 25,039—83.3% | 23,490—80.2% | 24,820—77.8% | 21,207—77.5% | |
| Total liabilities and equity | 33,859—100% | 33,859+7.5%100% | 33,633+5.2%100% | 27,930−4.3%100% | 30,079−1.6%100% | 31,487+4.8%100% | 31,965+9.1%100% | 29,187−8.5%100% | 30,560+11.8%100% | 30,057—100% | 29,301—100% | 31,899—100% | 27,347—100% | |
| Shares outstanding | 0.3—— | 0.3−93.9%— | 2.4−47.6%— | 4.9+81.2%— | 0.0r4.9−99.0%— | 4.6+128%— | 4.6+289%— | 2.7+172%— | 2.6+18313%— | 2.0—— | 1.2—— | 1.0—— | 0.0r28—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 328+10.0%0.9% | 75−22.1%0.8% | 78+7.5%0.8% | 77+18.6%1.0% | 99r99*+51.3%1.2% | 96+48.3%1.0% | 73+42.6%0.8% | 65+52.0%0.7% | 65*+54.4%0.7% | 65*—0.8% | 51*—0.5% | 43—0.6% | 42*—0.6% | |
| Cash from operating activities | −5,990—−16.9% | −1,384*—−14.7% | −918*—−9.9% | −2,072—−25.6% | −1,616r−1,616*—−18.8% | −747r−728*—−7.9% | −1,273r−1,273*—−13.5% | −1,695r−1,714—−19.0% | −3,405r−3,407*—−35.5% | −1,357r−1,361*—−16.1% | −4,578r−4,578*—−49.2% | −3,185r−3,185—−42.2% | −2,690*—−35.0% | |
| Capital expenditure | — | — | −7.0*—−0.1% | −5.1—−0.1% | — | −8.0*—−0.1% | −160*—−1.7% | −7.5—−0.1% | −103*—−1.1% | −517*—−6.1% | −975*—−10.5% | −63—−0.8% | — | |
| Intangible assets bought | — | −88*—−0.9% | — | −99—−1.2% | −41*—−0.5% | −26*—−0.3% | −390*—−4.1% | −205—−2.3% | — | −93*—−1.1% | — | −637—−8.4% | −686*—−8.9% | |
| Cash from investing activities | −134—−0.4% | 25*—0.3% | −5.1*—−0.1% | −105—−1.3% | −50*—−0.6% | −24r−118*—−0.3% | −550r−492*—−5.8% | −212r−176—−2.4% | −98r−532*—−1.0% | −671r−578*—−8.0% | −542*—−5.8% | −669—−8.9% | −269*—−3.5% | |
| Shares issued | — | 2,232*—23.6% | — | — | 0*—0.0% | 0*—0.0% | 1,829*—19.4% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 8,522—113% | 0*—0.0% | |
| Shares bought back | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −3,140—−41.6% | 0*—0.0% | |
| Cash from financing activities | 10,761+90.7%30.4% | 2,232*—23.6% | 7,804*+113%84.2% | 0−100%0.0% | 725*−55.2%8.4% | 0r76*−100%0.0% | 3,669r3,610*—39.0% | 355r338−93.4%4.0% | 1,618r2,054*—16.9% | 1,954r1,866*—23.2% | −29*—−0.3% | 5,398—71.6% | −31*—−0.4% | |
| Exchange-rate effect on cash | — | — | — | −34—−0.4% | — | — | — | −10−107%−0.1% | — | — | −141*—−1.5% | 141—1.9% | −63*—−0.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Sunshine Biopharma, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Sunshine Biopharma, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Steve N. Slilaty | $466 K | $466 K | $960 K | $0 |
| 2024Dr. Steve N. Slilaty | $1.2 M | $1.2 M | $639 K | $0 |
| 2023Dr. Steve N. Slilaty | $560 K | $560 K | $955 K | $0 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Sunshine Biopharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 3 · Material agreement 5 · Shareholder vote 6 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 14, 2026
Acquisitions and funding#
1 acquisitions, $19 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Nora Pharma | 2022 | — | $19 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2023 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Apr 2022 | $20 M | Private placement after listing | $10 to $50 million | 9 | equity, options | SEC |
| Mar 2022 | $8 M | Private placement after listing | $2 to $10 million | 9 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Sunshine Biopharma, Inc. compares in Pharmaceutical
- Market cap$3 M · higher than 2% of 393
- Revenue$36 M · higher than 12% of 324
- Net margin-17.4% · higher than 15% of 313
- Revenue growth4.1% · higher than 41% of 107
- Price / sales0.1× · lower than 99% of 219
- Price / book0.1× · lower than 99% of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sunshine Biopharma, Inc.🇨🇦 | $3 M | — | -17.4% | +4.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sunshine Biopharma, Inc.? Verify and update this profile — free
Show Sunshine Biopharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.